WuXi Biologics Announces Manufacturing Partnership with InflaRx
Tuesday, May 16, 2023
WuXi Biologics announced the manufacturing partnership with InflaRx for its COVID-19 treatment Gohibic (vilobelimab).
Under the terms of the agreement, WuXi Biologics will provide cGMP manufacturing of Gohibic, a first-in-class monoclonal anti-human complement factor C5a antibody.
The partnership represents another remarkable efforts to establish a robust manufacturing network on a global scale. Together this collaboration aims to ramp up production under high pressure to roll out supply in order to serve the patient population in need as soon as possible. With its advanced technology and proven expertise, WuXi Biologics greatly helped apply to the FDA for emergency use approval of Gohibic.
With a global manufacturing network that includes facilities in the United States, Ireland, Germany, China and Singapore, WuXi Biologics leverages its development and manufacturing technologies to provide more efficient and cost-effective production of drug substances (DS) and drug products (DP), delivering commercial biologics for global clients and enabling promising treatments delivered to patients worldwide.
